Mesoestetic Mesohyal Redenx

mesoestetic has added mesohyal redenx to its mesohyal range of intradermal medical devices, a skin booster formulated to address moderate ageing, loss of skin density and gravitational sagging, with particular focus on the lower third of the face.

The booster is administered intradermally and is formulated with biomimetic peptides and biorevitalising ingredients designed to mimic the body's natural signalling processes, stimulating collagen production, enhancing skin repair and improving firmness and vitality. It combines a tripeptide and a tetrapeptide to activate the synthesis proteins of the extracellular matrix, working on the redensification mechanisms that are impaired by the reduction of oestrogens and other factors characteristic of ageing. The formula contains 15mg/ml of hyaluronic acid delivered via non-crosslinked free hyaluronic acid, and is available in both a 3ml vial and a 2ml pre-filled syringe. A course consists of five sessions at 15-day intervals.

The product is particularly relevant to the often-neglected needs of menopausal skin. mesohyal redenx sits within the brand's widest CE-marked Class III intradermal medical device range, designed for use by aesthetic practitioners across facial and body indications.

mesoestetic was founded in 1985 by Joan Carles Font, starting in the back room of his pharmacy on Gran Vía in Barcelona, where he produced specific formulations for doctors who were beginning to practise aesthetic medicine but had no dedicated products available. The company reinvests 40% of its annual profits into research and development and now operates in more than 110 countries. In 2025, mesoestetic marks 40 years of operation. Its facilities are authorised by the Spanish Agency for Medicines and Medical Devices and cover three pharmaceutical manufacturing lines spanning cosmeceuticals, intradermal devices and injectable and topical drugs.

Available now at Mesoestetic.